We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Reporting of MABp1 for the Treatment of Psoriasis—Reply

Kyle M. Coleman, MD1; Johann E. Gudjonsson, MD, PhD2; Michael Stecher, MD3
[+] Author Affiliations
1Westlake Dermatology and Cosmetic Surgery, Austin, Texas
2Department of Dermatology, University of Michigan, Ann Arbor, Michigan
3XBiotech USA Inc, Austin, Texas
JAMA Dermatol. 2015;151(10):1144. doi:10.1001/jamadermatol.2015.1683.
Text Size: A A A
Published online


In Reply Thank you for allowing us the opportunity to respond to the commentators’ criticism and clarify the results from our recent report using MABp1 (Xilonix) in patients with moderate to severe plaque psoriasis.

To better clarify our findings, the inclusion criteria for this trial specified that all patients have a diagnosis of plaque psoriasis for 6 months or longer with an affected body surface area of at least 5% and a baseline Psoriasis Area Severity Index (PASI) of at least 12 (NCT01384630). At baseline, this study cohort included 8 patients with plaque psoriasis, 3 of whom also had a history of psoriatic arthritis.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





October 1, 2015
Bobbak Mansouri, MD; Alan Menter, MD
1Division of Dermatology, Baylor University Medical Center, Dallas, Texas
JAMA Dermatol. 2015;151(10):1143-1144. doi:10.1001/jamadermatol.2015.1684.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...